A phase 3 trial of azacitidine versus a semi‐intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
S Vives, D Martínez‐Cuadrón, J Bergua Burgues… - Cancer, 2021 - Wiley Online Library
BACKGROUND Options to treat elderly patients (≥ 65 years old) newly diagnosed with
acute myeloid leukemia (AML) include intensive and attenuated chemotherapy …
acute myeloid leukemia (AML) include intensive and attenuated chemotherapy …
[HTML][HTML] Maintenance decitabine (DAC) improves disease-free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults …
Background: Relapse remains the most common cause of treatment failure after intensive
induction and consolidation (CONS) therapy in older adults with AML. We therefore …
induction and consolidation (CONS) therapy in older adults with AML. We therefore …
Randomized trial of 10 days of decitabine±bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
GJ Roboz, SJ Mandrekar, P Desai, K Laumann… - Blood …, 2018 - ashpublications.org
Novel treatment strategies are needed for older patients with acute myeloid leukemia (AML).
This randomized phase 2 trial compared the efficacy and safety of 20 mg/m2 of IV decitabine …
This randomized phase 2 trial compared the efficacy and safety of 20 mg/m2 of IV decitabine …
[HTML][HTML] Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
DA Pollyea, J Zehnder, S Coutre, JR Gotlib… - …, 2013 - ncbi.nlm.nih.gov
There are limited treatment options for older patients with acute myeloid leukemia and
prognosis of these patients remains poor, thereby warranting development of novel …
prognosis of these patients remains poor, thereby warranting development of novel …
Pharmacokinetic evaluation of decitabine for the treatment of leukemia
J Bryan, H Kantarjian, G Garcia-Manero… - Expert Opinion On …, 2011 - Taylor & Francis
Introduction: Acute myeloid leukemia (AML) is a life-threatening malignancy that primarily
afflicts an elderly population. Treatment of elderly patients with intensive chemotherapy is …
afflicts an elderly population. Treatment of elderly patients with intensive chemotherapy is …
[HTML][HTML] Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy
HP Erba - Leukemia research, 2015 - Elsevier
There is no standard of care for older patients with newly diagnosed acute myeloid leukemia
(AML) unfit for intensive therapy, and prognosis with currently recommended low-intensity …
(AML) unfit for intensive therapy, and prognosis with currently recommended low-intensity …
Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2× 2, phase II …
M Lübbert, O Grishina, C Schmoor… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE DNA-hypomethylating agents are studied in combination with other epigenetic
drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in …
drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in …
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase …
CD DiNardo, A Maiti, CR Rausch… - The Lancet …, 2020 - thelancet.com
Background Venetoclax combined with hypomethylating agents is a new standard of care
for newly diagnosed patients with acute myeloid leukaemia (AML) who are 75 years or …
for newly diagnosed patients with acute myeloid leukaemia (AML) who are 75 years or …
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
R Briski, G Garcia-Manero… - Therapeutic …, 2023 - journals.sagepub.com
Decitabine, a member of the 5-azanucleosides, has a dose-dependent mechanism of action
in vitro: termination of DNA replication at high doses, and inhibition of DNA …
in vitro: termination of DNA replication at high doses, and inhibition of DNA …
How and when to decide between epigenetic therapy and chemotherapy in patients with AML
H Dombret, R Itzykson - Hematology 2014, the American …, 2017 - ashpublications.org
Remission induction with chemotherapy has long been the frontline treatment of acute
myeloid leukemia (AML). However, intensive therapy is limited in frail patients by its …
myeloid leukemia (AML). However, intensive therapy is limited in frail patients by its …